
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is a telehealth platform that is making waves in the healthcare industry. The company has a diversified portfolio of treatments and medications, and with more than 2 million subscribers, it has a wide reach. The recent partnership with Novo Nordisk, which includes the sale of the Wegovy pill, presents significant revenue potential for Hims & Hers. Additionally, the company's expansion into international markets and vertical integration efforts provide opportunities for long-term growth. The current regulatory and legal risks should not overshadow Hims & Hers' strong base and potential for growth.
Bears say
Hims & Hers Health is facing potential risks and regulation challenges in their compounded products, as well as potential litigation risks. However, their partnership with Novo Nordisk and expansion into new specialties and international markets show potential for increased revenue and margins, leading to a Buy rating and a $30 price target. Despite a cautious approach from analysts, Hims & Hers Health maintains positive relationships in the healthcare industry and expects growth in various areas, such as online orders and wholesale revenue.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares